FindTrial
Sign In

The study of serum trace elements in patients with acute myeloid leukemia: detection and clinical significance

The study of serum trace elements in patients with acute myeloid leukemia: detection and clinical significance - STEL-AML

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072783
Enrollment
Unknown
Registered
2023-06-25
Start date
2017-10-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukkemia

Interventions

Group of acute myeloid leukkemia:None
Healthy controls:None

Sponsors

the first hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 76 Years

Inclusion criteria

Inclusion criteria: ? A newly diagnosed patient with acute myeloid leukemia was confirmed by bone marrow morphology and immunophenotyping. ? Age = 18 years old. ?complete clinical data.

Exclusion criteria

Exclusion criteria: ? Incomplete clinical data. ? Previously suffering from diseases closely related to trace element metabolism.

Design outcomes

Primary

MeasureTime frame
Serum trace elements zinc, selenium, and copper levels;—

Countries

China

Contacts

Public ContactQiuju Liu

the first hospital of Jilin University

qjliu@jlu.edu.cn+86 187 0430 8063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026